Chronic myeloid leukemia stem cells, Leukemia, vol.33, pp.1543-1556, 2019. ,
International randomized study of interferon vs STI571 (IRIS) 8-year follow up: sustained survival and low risk for progression or events in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) treated with imatinib, Blood, vol.114, p.1126, 2009. ,
Nilotinib in imatinibresistant CML and Philadelphia chromosome-positive ALL, N Engl J Med, vol.354, pp.2542-2551, 2006. ,
Dasatinib in imatinibresistant Philadelphia chromosome-positive leukemias, N Engl J Med, vol.354, pp.2531-2541, 2006. ,
Ponatinib in refractory Philadelphia chromosome-positive leukemias, N Engl J Med, vol.367, pp.2075-2088, 2012. ,
Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION), Blood, vol.119, pp.1123-1129, 2012. ,
Life expectancy of patients with chronic myeloid leukemia approaches the life expectancy of the general population, J Clin Oncol, vol.34, pp.2851-2857, 2016. ,
Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro, Blood, vol.99, pp.319-325, 2002. ,
Chronic myeloid leukemia stem cells in the era of targeted therapies: resistance, persistence and longterm dormancy, Oncotarget, vol.2, pp.713-727, 2011. ,
Long-term follow-up of the French Stop Imatinib (STIM1) Study in patients with chronic myeloid leukemia, J Clin Oncol, vol.35, pp.298-305, 2017. ,
BCR-ABL expression in leukemic progenitors and primitive stem cells of patients with chronic myeloid leukemia, Blood, vol.119, pp.2964-2965, 2012. ,
Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study, Blood, vol.122, pp.515-522, 2013. ,
MADE4: an R package for multivariate analysis of gene expression data, Bioinformatics, vol.21, pp.2789-2790, 2005. ,
URL : https://hal.archives-ouvertes.fr/hal-00427730
FactoMineR: an R package for multivariate analysis, J Stat Softw, vol.25, issue.1, 2008. ,
Elegant Graphics for Data Analysis, 2009. ,
Diagnosis of multiple cancer types by shrunken centroids of gene expression, Proc Natl Acad Sci USA, vol.99, pp.6567-6572, 2002. ,
The dynamics and regulators of cell fate decisions are revealed by pseudotemporal ordering of single cells, Nat Biotechnol, vol.32, pp.381-386, 2014. ,
Personalized synthetic lethality induced by targeting RAD52 in leukemias identified by gene mutation and expression profile, Blood, vol.122, pp.1293-1304, 2013. ,
Chronic myeloid leukemia: mechanisms of blastic transformation, J Clin Invest, vol.120, pp.2254-2264, 2010. ,
Human chronic myeloid leukemia stem cells are insensitive to imatinib despite inhibition of BCR-ABL activity, J Clin Invest, vol.121, pp.396-409, 2011. ,
Combination of ponatinib with hedgehog antagonist vismodegib for therapy-resistant BCR-ABL1-positive leukemia, Clin Cancer Res, vol.19, pp.1422-1432, 2013. ,
Hedgehog signalling is essential for maintenance of cancer stem cells in myeloid leukaemia, Nature, vol.458, pp.776-779, 2009. ,
The STAT5 inhibitor pimozide decreases survival of chronic myelogenous leukemia cells resistant to kinase inhibitors, Blood, vol.117, pp.3421-3429, 2011. ,
PML targeting eradicates quiescent leukaemia-initiating cells, Nature, vol.453, pp.1072-1078, 2008. ,
Loss of the Alox5 gene impairs leukemia stem cells and prevents chronic myeloid leukemia, Nat Genet, vol.41, pp.783-792, 2009. ,
Transcriptional regulation by NR5A2 links differentiation and inflammation in the pancreas, Nature, vol.554, pp.533-537, 2018. ,
Single-cell RNA-Seq analysis of infiltrating neoplastic cells at the migrating front of human glioblastoma, Cell Rep, vol.21, pp.1399-1410, 2017. ,
Single-cell transcriptomics uncovers distinct molecular signatures of stem cells in chronic myeloid leukemia, Nat Med, vol.23, pp.692-702, 2017. ,
Resolving medulloblastoma cellular architecture by single-cell genomics, Nature, vol.572, pp.74-79, 2019. ,
Pan-cancer genome and transcriptome analyses of 1,699 paediatric leukaemias and solid tumours, Nature, vol.555, pp.371-376, 2018. ,
Single-cell molecular analysis defines therapy response and immunophenotype of stem cell subpopulations in CML, Blood, vol.129, pp.2384-2394, 2017. ,
Lin28 promotes transformation and is associated with advanced human malignancies, Nat Genet, vol.41, pp.843-848, 2009. ,
BCR-ABL fails to inhibit apoptosis in U937 myelomonocytic cells expressing a carboxyl-terminal truncated STAT5, Leuk Lymphoma, vol.42, pp.445-455, 2001. ,
Essential role for Stat5a/ b in myeloproliferative neoplasms induced by BCR-ABL1 and JAK2(V617F) in mice, Blood, vol.119, pp.3550-3560, 2012. ,
Differential contributions of STAT5A and STAT5B to stress protection and tyrosine kinase inhibitor resistance of chronic myeloid leukemia stem/progenitor cells, Cancer Res, vol.73, pp.2052-2058, 2013. ,
STAT5 as a CML target: STATinib therapies?, Blood, vol.117, pp.3252-3253, 2011. ,
Targeting the JAK2-STAT5 pathway in CML, Blood, vol.124, pp.1386-1388, 2014. ,
JAK of all trades: JAK2-STAT5 as novel therapeutic targets in BCR-ABL1+ chronic myeloid leukemia, Blood, vol.122, pp.2167-2175, 2013. ,
Pushing the limits of targeted therapy in chronic myeloid leukaemia, Nat Rev Cancer, vol.12, pp.513-526, 2012. ,
Leukotriene signaling via ALOX5 and cysteinyl leukotriene receptor 1 is dispensable for in vitro growth of CD34 + CD38 ? stem and progenitor cells in chronic myeloid leukemia, Biochem Biophys Res Commun, vol.490, pp.378-384, 2017. ,
Low leukotriene B4 receptor 1 leads to ALOX5 downregulation at diagnosis of chronic myeloid leukemia, Haematologica, vol.99, pp.1710-1715, 2014. ,
JAK2/STAT5 inhibition by nilotinib with ruxolitinib contributes to the elimination of CML CD34+ cells in vitro and in vivo, Blood, vol.124, pp.1492-1501, 2014. ,